The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Nanoparticle targeting of de novo profibrotic macrophages mitigates lung fibrosis
Open accessAbstract
Significance: Current therapies for pulmonary fibrosis (PF) focus on slowing disease progression and reducing functional decline in patients by dampening the activation of fibroblasts and other implicated cells. There is a need for strategies that target the essential cells and signaling pathways involved in disease pathogenesis. Monocyte-derived macrophages (Mo-Macs) are known to express profibrotic genes and are involved in the pathogenesis of PF. Our results show that engineered mannosylated albumin nanoparticles specifically targeted disease-inducing Mo-Macs, and further, that nanoparticles efficiently delivered small-interfering RNA against profibrotic cytokine tumor growth factor β1 to prevent bleomycin-induced lung fibrosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For instance, mannose-modified albumin nanoparticles delivering TGF-b1 siRNA have been shown to effectively attenuate pulmonary fibrosis severity in murine models (157).”
From The mechanotransduction-immune axis in organ fibrosis: dual regulatory mechanisms and translational therapeutic perspectives (2025) · doi:10.3389/fimmu.2025.1670213 · cites this paper as [157]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Aran, D., Looney, A. P., Liu, L., Wu, E., Fong, V., Hsu, A., Chak, S., Naikawadi, R. P., Wolters, P. J., Abate, A. R., et al. (2019) · Nature Immunology · doi:10.1038/s41590-018-0276-y · Cited by 4,984 · cited 9×
“Cx3cr1CreERT2 mice were administered tamoxifen (75 mg/kg body weight) via intraperitoneal injection starting before 1 wk of bleomycin instillation and continuing every other day throughout the treatment for Cre induction (17).”
BackgroundMethodResultInfluentialOrecchioni, M., Ghosheh, Y., Pramod, A. B., & Ley, K. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01084 · Cited by 2,063
Fibrosis: from mechanisms to medicines
Henderson, N. C., Rieder, F., & Wynn, T. A. (2020) · Nature · doi:10.1038/s41586-020-2938-9 · Cited by 1,868
Clinical course and prediction of survival in idiopathic pulmonary fibrosis
Ley, B., Collard, H. R., & King, T. E. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201006-0894ci · Cited by 1,765
Albumin-based nanoparticles as potential controlled release drug delivery systems
Elzoghby, A. O., Samy, W. M., & Elgindy, N. A. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.07.031 · Cited by 1,520
Monocyte-derived alveolar macrophages drive lung fibrosis and persist in the lung over the life span
Misharin, A. V., Morales-Nebreda, L., Reyfman, P. A., Cuda, C. M., Walter, J. M., McQuattie-Pimentel, A. C., Chen, C.-I., Anekalla, K. R., Joshi, N., Williams, K. J. N., et al. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20162152 · Cited by 1,133 · cited 7×
“Mo-Macs in response to inflammatory cues also migrated into the lung airspace and transitioned into de novo AMs, referred to as Mo-AMs (12, 17).”
BackgroundInfluentialPulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy
George, P. M., Wells, A. U., & Jenkins, R. G. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30225-3 · Cited by 1,085
TGF-β-induced EMT: mechanisms and implications for fibrotic lung disease
Willis, B. C., & Borok, Z. (2007) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00163.2007 · Cited by 1,042
Moeller, A., Ask, K., Warburton, D., Gauldie, J., & Kolb, M. (2008) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.08.011 · Cited by 1,007
Flow Cytometric Analysis of Macrophages and Dendritic Cell Subsets in the Mouse Lung
Misharin, A. V., Morales-Nebreda, L., Mutlu, G. M., Budinger, G. R. S., & Perlman, H. (2013) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2013-0086ma · Cited by 838
Research works printed but not linked: 1
- Health NIo, Idiopathic Pulmonary Fibrosis Frequency (US National Library of Medicine, 2020).
Cited by
Biology of lung macrophages in health and disease
Aegerter, H., Lambrecht, B. N., & Jakubzick, C. V. (2022) · Immunity · doi:10.1016/j.immuni.2022.08.010 · Cited by 621
Malainou, C., Abdin, S. M., Lachmann, N., Matt, U., & Herold, S. (2023) · Journal of Clinical Investigation · doi:10.1172/jci170501 · Cited by 201
Lipid Nanoparticles Optimized for Targeting and Release of Nucleic Acid
Jia, Y., Wang, X., Li, L., Li, F., Zhang, J., & Liang, X. (2023) · Advanced Materials · doi:10.1002/adma.202305300 · Cited by 171
Enomoto, Y., Katsura, H., Fujimura, T., Ogata, A., Baba, S., Yamaoka, A., Kihara, M., Abe, T., Nishimura, O., Kadota, M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40617-y · Cited by 131
Monocytes and macrophages: emerging mechanisms and novel therapeutic targets in pulmonary fibrosis
Perrot, C. Y., Karampitsakos, Τ., & Herazo‐Maya, J. D. (2023) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00302.2023 · Cited by 103
Metadata
- Authors
- Singh, A., Chakraborty, S., Wong, S. W., Hefner, N. A., Stuart, A., Qadir, A. S., Mukhopadhyay, A., Bachmaier, K., Shin, J.-W., Rehman, J., & Malik, A. B.
- Affiliations
- University of Illinois Chicago (US)
- Corresponding author
- Malik, Asrar B.
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2022-04-04
- Volume
- 119
- Issue
- 15
- Pages
- e2121098119-e2121098119
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC9169714
- OpenAlex
- W4224117100
- Cited by
- 107
- References
- 57
- Citations by year
- 2026: 22 · 2025: 34 · 2024: 24 · 2023: 20 · 2022: 7
- FWCI
- 13.70
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- HHS | NIH | National Heart, Lung, and Blood Institute (T32HL007829, R41HL126456, R42HL126456, P01HL151327, R01HL141255)
- HHS | NIH | National Institute of General Medical Sciences (R01GM141147)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- pulmonary fibrosis, macrophage targeting, TGF-β1, siRNA delivery, monocyte-derived macrophages, alveolar macrophages, interstitial macrophages, nanoparticle uptake, extracellular matrix remodeling, antifibrotic therapy
- MeSH terms
- Mannose Receptor, Animals, Bleomycin, Disease Models, Animal, Lymphotoxin-alpha, Mice, Inbred C57BL, Pulmonary Fibrosis, Macrophages, Alveolar, RNA, Small Interfering, Mice, Nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Nanoparticle targeting of de novo profibrotic macrophages mitigates lung fibrosis. https://app.cochat.ai/papers/10.1073/pnas.2121098119
- The paper
- Singh, A., Chakraborty, S., Wong, S. W., Hefner, N. A., Stuart, A., Qadir, A. S., Mukhopadhyay, A., Bachmaier, K., Shin, J.-W., Rehman, J., & Malik, A. B. (2022). Nanoparticle targeting of de novo profibrotic macrophages mitigates lung fibrosis. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2121098119
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.